

# **Environmental Risk Assessment Summary Baloxavir marboxil**

#### Introduction

The publication of environmental risk assessment summaries is part of Roche's engagement on developing a better understanding of issues regarding pharmaceuticals in the environment (PiE).

New pharmaceutical substances are investigated for biodegradability and initial ecotoxicity during their development. For registration, a full state-of-the-art environmental risk assessment is developed based on chronic environmental effects and advanced environmental fate data, as required by the pertinent regulations. While not a regulatory requirement, Roche also investigates older pharmaceutical substances, normally at a simpler scale, in order to assess their environmental risks.

For active pharmaceutical ingredients, the potential environmental risk is calculated from the ratio between the Predicted Environmental Concentration (PEC) of the substance in the aquatic environment based on a conservative emission scenario and the Predicted No Effect Concentration (PNEC), a concentration below which no adverse effects on the environment have to be expected.

#### **Summary**

Baloxavir marboxil is an antiviral medicine for treating and preventing flu in adults and children from 12 years of age. Baloxavir marboxil is the pharmaceutical active substance in the Roche product Xofluza [16].

Baloxavir marboxil is a prodrug and converted to the active substance Baloxavir through metabolism (hydrolysis). Baloxavir selectively inhibits targets necessary for replication of influenza viruses and shows potent inhibitory effects on virus replication.

The Environmental Risk Assessment is performed for the active substance Baloxavir.

Baloxavir marboxil is not readily biodegradable [4]. In a sediment/water study with Baloxavir over 100 days, >90% of the applied radioactivity was observed in the sediment as non-extractable residues (NER) [11].

The PEC/PNEC ratio is 0.002. With reference to the Guideline on the Environmental Risk Assessment on Medicinal Products for Human Use of the European Medicines Agency [15], a PEC/PNEC ratio of <1 means that Baloxavir and/or its metabolites are unlikely to represent a risk to the aquatic environment.



## **Predicted Environmental Concentration (PEC)**

The PEC is based on the following data:

PEC (mg/L) = (MDD × 
$$10^3$$
 ×  $F_{PEN-REFINED}$ ) ÷ (V × D)

MDD Maximal daily dose (Baloxavir marboxil) = 80 mg/d

Maximal daily dose (Baloxavir) = 67.7 mg/d

 $F_{PEN-REFINED}$  Based on prevalence of the diseases: 0.00055

V Volume of wastewater per inhabitant and day (default value) = 200 L day<sup>-1</sup> [15]
D Dilution factor of wastewater by surface water flow (default value) = 10 [15]

PEC =  $0.019 \mu g/L$  (as Baloxavir)

*Note*: Baloxavir is at least partially metabolised in the body. Since little is known about the ecotoxicity

of these metabolites, it is assumed as a worst case that they have the same ecotoxicological

relevance as Baloxavir.

#### **Predicted No Effect Concentration (PNEC)**

Chronic studies have been performed for Baloxavir for species from three trophic levels, based on OECD Test Guidelines [17]. The lowest NOEC is 0.092 mg/L (92  $\mu$ g/L) assessed in a toxicity test with green algae [6]. Applying an assessment factor of 10 according to the EMA Guideline [15], this results in a PNEC value of 9.2  $\mu$ g/L.

 $PNEC = 92 \text{ mg/L} / 10 = 9.2 \mu g/L$ 

#### **PEC/PNEC** ratio

PEC =  $0.019 \mu g/L$ PNEC =  $9.2 \mu g/L$ 

PEC/PNEC = 0.002

With reference to the Guideline on the Environmental Risk Assessment on Medicinal Products for Human Use of the European Medicines Agency [15], a PEC/PNEC ratio of 0.002 (i.e. <1) means that Baloxavir and/or its metabolites are unlikely to represent a risk to the aquatic environment.



# Aquatic Toxicity Data for Baloxavir marboxil (BVM) and Baloxavir (BV)

Study	Guideline	Results	Test item	Ref.
Growth inhibition test with	OECD 201	72 h EC50 (growth rate) 9.28 mg/L MMC	BVM	[1]
green algae (Desmodesmus		72 h EC50 (yield) 4.76 mg/L MMC		. ,
subspicatus)		72 h EC10 (growth rate) 4.20 mg/L MMC		
•		72 h EC10 (yield) 2.02 mg/L MMC		
		72 h NOEC 1.75 mg/L MMC		
Growth inhibition test with	OECD 201	72 h EC50 (growth rate) >3.2 mg/L MMC	BV	[6]
green algae (Raphidocelis		72 h EC50 (yield) 0.46 mg/L MMC		
subcapitata)		72 h NOEC 0.092 mg/L MMC		
Acute immobilisation test	OECD 202	48 h EC50 >17.4 mg/L IMC	BVM	[2]
with Daphnia magna		48 h NOEC 17.4 mg/L IMC		
Daphnia magna,	OECD 211	21 d EC10 1.5 mg/L MMC	BV	[7]
Reproduction Test		21 d NOEC 0.44 mg/L MMC		
Acute toxicity to zebrafish	OECD 203	96 h LC50 >10.6 mg/L MMC	BVM	[3]
(Danio rerio)		96 h NOEC 10.6 mg/L MMC		
Fish, early-life stage toxicity	OECD 210	36 d EC10 (hatching success) 0.11 mg/L	BV	[8]
test with fathead minnow		MMC		
(Pimephales promelas)				
Chronic toxicity to	OECD 218	28 d EC50 >1000 mg/kg NC	BV	[9]
sediment-dwelling		28 d LOEC 1000 mg/kg NC		
Chironomus riparius		28 d NOEC 320 mg/kg NC		
Activated sludge respiration inhibition test	OECD 209	3 h EC50 56 mg/L NC	BV	[10]

EC10 concentration of the test substance that results in 10% effect EC50 concentration of the test substance that results in 50% effect

NOEC No observed effect concentration
 IMC Initially measured concentration
 MMC Mean measured concentration
 NC Nominal concentration



## **Environmental Fate Data for Baloxavir marboxil (BVM) and Baloxavir (BV)**

Study	Guideline	Results	Test item	Ref.
Ready biodegradability	OECD 301 F	BOD ÷ ThOD (mineralisation)	BVM	[4]
		0% after 28 d		
Aerobic transformation in aquatic sediment systems	OECD 308	DT50 (total system) >120 d	BV	[11]
Soil Adsorption Coefficient	OECD 106	$K_{OC} = 107,000-186,000 \text{ L/kg}$	BV	[12]
Sludge Adsorption	OECD 106	$K_{OC} = 16,200-44,000 \text{ L/kg}$	BV	[12]
Coefficient				

BOD Biochemical oxygen demand ThOD Theoretical oxygen demand

DT50 Half life

K<sub>OC</sub> Adsorption distribution coefficient, corrected for organic carbon content

TOC Total organic carbon

## Physical Chemical Data for for Baloxavir marboxil (BVM) and Baloxavir (BV)

Study	Guideline	Results	Test item	Ref.
Water solubility	OECD 105	5.1 mg/L (pH 7, 20 °C)	BV	[13]
n-Octanol-water	OECD 117	logD <sub>OW</sub> 2.5 (pH 5, 25 °C)	BVM	[5]
distribution coefficient	OECD 117	logD <sub>OW</sub> 2.5 (pH 7, 25 °C)	BVM	[5]
	OECD 117	logD <sub>OW</sub> 2.5 (pH 9, 25 °C)	BVM	[5]
	OECD 107	logD <sub>OW</sub> 2.0 (pH 5, 20 °C)	BV	[14]
	OECD 107	logD <sub>OW</sub> 2.0 (pH 7, 20 °C)	BV	[14]
	OECD 107	logD <sub>OW</sub> 1.1 (pH 9, 20 °C)	BV	[14]

#### References

- [1] Arcadis Schweiz LTD, on behalf of F. Hoffmann-La Roche Ltd (2019): Baloxavir marboxil: Fresh water algal growth inhibition test with *Raphidocelis subcapitata*; OECD 201. ACH study no. A18-02432
- [2] Arcadis Schweiz LTD, on behalf of F. Hoffmann-La Roche Ltd (2019): Baloxavir marboxil: Acute immobilisation test with *Daphnia magna*; OECD 202. ACH study no. A18-02433
- [3] Arcadis Schweiz LTD, on behalf of F. Hoffmann-La Roche Ltd (2019): Baloxavir marboxil: Acute test with *Danio rerio*; OECD 203. ACH study no. A18-02434
- [4] Arcadis Schweiz LTD, on behalf of F. Hoffmann-La Roche Ltd (2019): Baloxavir marboxil: Ready biodegradability in an aerobic, aqueous medium: Manometric Respirometry Test; OECD 301 F. ACH study no. A18-02435
- [5] Arcadis Schweiz LTD, on behalf of F. Hoffmann-La Roche Ltd (2019): Baloxavir marboxil: Determination of the partition coefficient between octanol and water by high performance liquid chromatography (HPLC); OECD 117. ACH study no. A18-02431



- [6] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Toxicity of Baloxavir to *Pseudokirchneriella subcapitata* in a 72-hour Algal Growth Inhibition Test; OECD 201. Envigo study no. TC37MV
- [7] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2018): Effect of Baloxavir on Survival and Reproduction of *Daphnia magna* in a Semi-Static Test over Three Weeks; OECD 211. Envigo study no. SG67FT
- [8] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2018): Toxic Effects of Baloxavir to Fathead Minnow (*Pimephales promelas*) in an Early-Life Stage Toxicity Test; OECD 210. Envigo study no. GY73WB
- [9] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2018): Effects of Baloxavir on the Development of Sediment-Dwelling Larvae of *Chironomus riparius* in Water-Sediment Systems with Spiked Sediment; OECD 218. Envigo study no. VX09WG
- [10] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Toxicity of Baloxavir to Activated Sludge in a Respiration Inhibition Test; OECD 209. Envigo study no. VF05RV
- [11] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Route and Rate of Degradation of [14C]-Baloxavir in Aerobic Aquatic Sediment Systems; OECD 308. Envigo study no PVO7LY
- [12] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Adsorption/Desorption of [14C]-Baloxavir on Three Soils and Two Sludges; OECD 106. Envigo study no NX1OCQ
- [13] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Determination of Baloxavir Water Solubility; OECD 105. Envigo study no. TC49XM
- [14] Envigo Research Limited, on behalf of Shionogi & Co., Ltd (2017): Determination of Baloxavir Partition Coefficient (Shake Flask Method); OECD 107. Envigo study no. MS75NV
- [15] European Medicines Agency (EMA) (2006/2015): Guideline on the environmental risk assessment of medicinal products for human use. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), 01 June 2006, EMA/CHMP/SWP/447/00 corr 2
- [16] F. Hoffmann-La Roche Ltd (2021). Safety data sheet for Baloxavir marboxil, 13 October 2021. https://www.roche.com/sustainability/environment/global product strategy and safety data sheets.htm
- [17] Organisation for Economic Co-operation and Development (OECD). OECD Guidelines for the Testing of Chemicals.

  <a href="http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm">http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm</a>